Leo Creative

  • Home
  • About
  • Our Approach
  • Our Work
    • Branding
    • Healthcare
  • Contact

Launching a new treatment for Dupuytren’s contracture

Client: Janssen Australia

dupuytens

Leo Creative worked with Janssen on the Australian launch of collagenase – a non-surgical TGA approved treatment for Dupuytren’s contracture. Like most pharma branding, the creative was done overseas, so the task was to adapt global brand assets for the local Australia market.

A wide range of collateral was produced including mandatory items like product information and consumer medicine information, printed detail aid and e-detailer (Veeva iRep), physician and patient guides.

Filed Under: work

Women and HIV

Client: Abbott Virology In 2010, US Treatment Guidelines identified lopinavir/ritonavir as the preferred protease inhibitor for the treatment of HIV-Infected women during pregnancy. The result … MORE

PAH Clinic

Client: Janssen Australia Janssen is a global leader in the science and medicine of Pulmonary Arterial Hypertension having launched the first endothelin receptor antagonist (ERA) bostentan, … MORE

What we believe about pharma branding

Over the last decade, the pharmaceutical industry has seen significant change. There are many views on the role of branding. We have heard champions of ‘customer centric’ sales models pronounce the … MORE

The role of branding in highly specialised markets

In our post “What we believe about pharma branding”, we gave a brief overview of the history of branding and the adoption of the FMCG branding model by big pharma where value is driven by the … MORE

Copyright © 2026 Leo Creative Pty Ltd · Genesis Framework by StudioPress · Log in